Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Alzheimer, Novo Nordisk and GLP-1

Digest more
 · 5h · on MSN
Analysis-Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention
Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs should be tested to prevent the disease in people at risk.

Continue reading

 · 1d
GLP-1 Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials
 · 1d · on MSN
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
5h

Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...
Scientific American
1d

GLP-1 Pill Fails to Slow Alzheimer’s Progression in Clinical Trial

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...
18h

Ozempic Pill Flops in Major Trials for Alzheimer’s

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
Feedback
  • Privacy
  • Terms